Skip to main
TSHA

TSHA Stock Forecast & Price Target

TSHA Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Taysha Gene Therapies is a promising investment as evidenced by the company's strong pipeline, with its lead candidate TSHA-102 showing promising and differentiated efficacy data, a strong safety profile utilizing a well-validated delivery platform, and a potential for favorable reimbursement based on early results. Taysha's recent updates on clinical data and regulatory progress further support a positive outlook on the company's potential in the gene therapy space.

Bears say

Taysha Gene Therapies is operating in a highly competitive market, with several companies actively pursuing gene therapy treatments for CNS disorders like Rett Syndrome. Additionally, production issues can limit the supply of development candidates, and reimbursement for high-priced gene therapy treatments may be challenging. While the company's use of the well-established AAV9 mitigates some risks, increased penetration in each indication could lead to reduced revenues in the long term.

TSHA has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Taysha Gene Therapies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Taysha Gene Therapies (TSHA) Forecast

Analysts have given TSHA a Strong Buy based on their latest research and market trends.

According to 10 analysts, TSHA has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Taysha Gene Therapies (TSHA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.